



SPAFID
CONNECT

Informazione Regolamentata n. 0957-79-2021	Data/Ora Ricezione 21 Dicembre 2021 10:29:47	Euronext Milan
--	--	----------------

Societa' : DiaSorin

Identificativo : 155580

Informazione
Regolamentata

Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio
Vaccarone

Tipologia : REGEM

Data/Ora Ricezione : 21 Dicembre 2021 10:29:47

Data/Ora Inizio : 21 Dicembre 2021 10:29:49

Diffusione presunta

Oggetto : DiaSorin S.p.A. - 2022 Annual Calendar of
Corporate Events

Testo del comunicato

Please see the attachment.

DIASORIN S.P.A. 2022 ANNUAL CALENDAR OF CORPORATE EVENTS*

Saluggia, December 21, 2021

Board of Directors

March 16, 2022	Draft Statutory Financial Statements 2021 and Consolidated Financial Statements 2021 approval
May 12, 2022	First Quarter 2022 results approval
July 29, 2022	Half-Yearly Financial Report approval
November 10, 2022	Third Quarter 2022 results approval

Shareholders' Meeting

April 29, 2022	Annual General Meeting for: (i) Statutory Financial Statements 2021 approval; (ii) Report on the remuneration policy and fees paid approval; (iii) election of corporate bodies.
-----------------------	---

* Indicative dates subject to change. Any changes will be communicated without delay.

In addition, the Company notifies that the month envisaged for the payment of any dividend in relation to 2021 results is May 2022. The information herein reported is given for the exclusive purpose of complying with the relevant Borsa Italiana S.p.A. regulations and cannot be interpreted or considered in any way as a forecast on the occurrence of the requirements for the distribution of dividends.

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Emanuela Salvini
Investor Relator
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist". More info at www.diasoringroup.com

Fine Comunicato n.0957-79

Numero di Pagine: 3